Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website https://www.journalmc.org

Case Report

Volume 15, Number 2-3, April 2024, pages 37-42

Renal Function Improvement With Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Type 2 Diabetes

Figures

Figure 1.
Figure 1. Changes in the treatments for type 2 diabetes, estimated glomerular filtration rate (eGFR) and hemoglobin A1c (a) and body weight (b).
Figure 2.
Figure 2. Changes in hemoglobin A1c and estimated glomerular filtration rate (eGFR) after the start of oral semaglutide.
Figure 3.
Figure 3. Changes in body weight (a), systolic and diastolic blood pressures (b), postprandial glucose, the peak of daily glucose (c) and average value of daily glucose (d) after the start of oral semaglutide. Thin vertical lines and continuous lines indicate daily values and average values of 1 week, respectively.
Figure 4.
Figure 4. Renal protective effect of SGLT2i-mediated normalization of tubulo-glomerular feedback in patients with classical diabetic nephropathy. eGFR: estimated glomerular filtration; Glu: glucose; SGLT2i: sodium-glucose co-transporter 2 inhibitor; TGF: tubulo-glomerular feedback.
Figure 5.
Figure 5. Unfavorable effect of SGLT2i-mediated normalization of tubulo-glomerular feedback on renal function in patients with hypertensive nephrosclerosis. eGFR: estimated glomerular filtration; Glu: glucose; SGLT2i: sodium-glucose co-transporter 2 inhibitor; TGF: tubulo-glomerular feedback.